Home

Healthcare

Summary

Sales of Teva's CNS portfolio, including Ajovy, Uzedy, and Austedo, rose 42.1% year-on-year to $837 million in Q1.

In my opinion, this growth, combined with the acquisition of Emalex, was the driver that pushed TEVA stock from the lower end of the distribution to $35.70.

As I'll explain below, Emalex's ecopipam is significantly less effective than Abilify, for which generic versions have been produced since 2015, including by Teva.

Results from Phase 3s evaluating duvakitug, developed jointly with Sanofi, for the treatment of Crohn's disease and UC will not be available until the end of 2028/Q1 2029.

Given that TEVA trades at the non-GAAP P/E ratio of 14.93x, which is 65.9% higher than Sanofi's, I continue to cover the Israeli generic drug giant with a 'Sell' rating.

Adriana Duduleanu/iStock via Getty Images

So, since my December article , "Teva Pharmaceuticals: Why It's Time To Cash Out", Teva shares ( TEVA ) have fluctuated between $28 and $36.3.

Meanwhile, for investors…